Insulet Corporation (PODD) : 4 days before expiry, shorts in Insulet Corporation (PODD) have reduced from 4,998,918 on Jul 29, 2016, to 4,492,960 on August 15, 2016. On an average, 1,000,866 shares are traded on the exchange. The outstanding bearish positions are equal to 8% of the float. Short sellers have covered -505,958 shares, a reduction of -10.1%, which underlines that they dont expect the stock to fall further from the current levels. The short interest information was released on Wednesday Aug 24th after the market close.
Insulet Corporation (NASDAQ:PODD): The stock opened at $43.02 on Wednesday but the bulls could not build on the opening and the stock topped out at $43.56 for the day. The stock traded down to $42.37 during the day, due to lack of any buying support eventually closed down at $42.44 with a loss of -2.10% for the day. The stock had closed at $43.35 on the previous day. The total traded volume was 259,223 shares.
In a related news, According to the information disclosed by the Securities and Exchange Commission in a Form 4 filing, the director of Insulet Corp, Sommer Regina O had sold 8,019 shares worth of $243,938 in a transaction dated May 25, 2016. In this transaction, 8,019 shares were sold at $30.42 per share.
Insulet Corporation is a medical device company engaged in the development, manufacturing and sale of the OmniPod Insulin Management System (the OmniPod System), an insulin infusion system for people with insulin-dependent diabetes. The Companys principal offices are located in Billerica, Massachusetts. Features of the OmniPod System include two-part design, no tubing, and automated cannula insertion. The OmniPod System consists of two devices that communicate wirelessly: the OmniPod, a small, lightweight, disposable insulin infusion device worn beneath clothing; and the PDM, a handheld device much like a personal digital assistant that wirelessly programs the OmniPod with insulin delivery instructions. The OmniPod will operate up to 72 hours (but no more than 80 hours) after it is first activated. The OmniPod System does not have external tubing and features an automated, hands-free cannula insertion system.